Literature DB >> 32672572

Micropulse Transscleral Diode Laser Cyclophotocoagulation in Refractory Glaucoma: Short-Term Efficacy, Safety, and Impact of Surgical History on Outcomes.

Giancarlo A Garcia1, Christine V Nguyen2, Aleksandr Yelenskiy2, Goichi Akiyama2, Brett McKnight2, Vikas Chopra2, Kenneth Lu2, Alex Huang2, James C H Tan2, Brian A Francis3.   

Abstract

PURPOSE: To assess the short-term efficacy and safety of micropulse transscleral diode laser cyclophotocoagulation (MP-TSCPC) in the management of refractory glaucoma and to compare outcomes based on prior glaucoma surgeries.
DESIGN: Retrospective analysis. PARTICIPANTS: Patients with refractory glaucoma who underwent MP-TSCPC at a single institution by 1 of 4 surgeons.
METHODS: Chart review of cases of MP-TSCPC using the Iridex Cyclo G6 (Mountain View, CA) laser with standard parameters and laser duration at the discretion of each treating physician. MAIN OUTCOME MEASURES: Probability of postoperative success was estimated by the Kaplan-Meier method. Success parameters included intraocular pressure (IOP) 6 to 21 mmHg with or without topical antihypertensive therapy, 20% or more IOP reduction from baseline for any 2 consecutive visits after 3 postoperative months, and no subsequent glaucoma surgery.
RESULTS: One hundred sixteen eyes of 116 patients (mean age, 65.8±16.9 years) were included. Baseline IOP was 22.2±7.9 mmHg, and mean postoperative follow-up time was 6.3±3.4 months (range, 3-12 months.) Postoperative IOP at the final follow up was 15.3±6.6 mmHg (P < 0.01), corresponding to a reduction of approximately 6.9 mmHg (31.1%). Most eyes (66.4%) underwent at least 6 months of follow-up. Short-term probability of success was 93.1% at 3 months and 74.3% at 6 months. Eyes that had undergone prior traditional glaucoma surgery (trabeculectomy, tube shunt, excessive pressure-regulating shunt system miniature glaucoma shunt [Alcon, Fort Worth, TX], or a combination thereof) demonstrated a higher probability of success (67.6%) compared with eyes that had not (41.4%; P = 0.014). The most common complications were decline in best-corrected visual acuity (7.8%) and hypotony (1.7%).
CONCLUSIONS: Micropulse transscleral diode laser cyclophotocoagulation has a significant short-term ocular hypotensive effect and favorable safety profile in eyes with refractory glaucoma. The probability of successful outcome was greater in eyes that had undergone prior traditional glaucoma surgery.
Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 32672572     DOI: 10.1016/j.ogla.2019.08.009

Source DB:  PubMed          Journal:  Ophthalmol Glaucoma        ISSN: 2589-4196


  8 in total

Review 1.  Clinical outcomes of slow-coagulation continuous-wave transscleral cyclophotocoagulation laser for treatment of glaucoma.

Authors:  Mohamed M Khodeiry; Xiangxiang Liu; Richard K Lee
Journal:  Curr Opin Ophthalmol       Date:  2022-02-23       Impact factor: 4.299

2.  Micropulse Transscleral Cyclophotocoagulation for Glaucoma after Penetrating Keratoplasty.

Authors:  Mihail Zemba; Otilia-Maria Dumitrescu; Alina-Cristina Stamate; Ileana Ramona Barac; Calin Petru Tataru; Daniel Constantin Branisteanu
Journal:  Diagnostics (Basel)       Date:  2022-05-05

3.  Evidence-Based Consensus Guidelines Series for MicroPulse Transscleral Laser Therapy: Dosimetry and Patient Selection.

Authors:  Tomas M Grippo; Ronald M P C de Crom; Michael Giovingo; Marc Töteberg-Harms; Brian A Francis; Brian Jerkins; Jacob W Brubaker; Nathan Radcliffe; Jella An; Robert Noecker
Journal:  Clin Ophthalmol       Date:  2022-06-07

4.  MicroPulse Transscleral Laser Therapy Demonstrates Similar Efficacy with a Superior and More Favorable Safety Profile Compared to Continuous-Wave Transscleral Cyclophotocoagulation.

Authors:  Enrico Bernardi; Marc Töteberg-Harms
Journal:  J Ophthalmol       Date:  2022-02-08       Impact factor: 1.909

5.  Outcomes of a combination of augmented MicroPulse and limited Continuous Wave Cyclophotocoagulation in patients with refractory glaucoma.

Authors:  Sanchay Gupta; Enchi Kristina Chang; Marika Chachanidze; Nathan Hall; Cameron Neeson; Emma Klug; Ta Chen Chang; David A Solá-Del Valle
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-10-25       Impact factor: 3.117

6.  Estimating the Ideal Treatment Protocol and Success Predictors for Double-session Micropulse Transscleral Laser for Glaucoma Management.

Authors:  Leopoldo Magacho; Francisco E Lima; Marcos P Ávila
Journal:  J Curr Glaucoma Pract       Date:  2022 May-Aug

7.  Ciliochoroidal effusion and its association with the outcomes of micropulse transscleral laser therapy in glaucoma patients: a pilot study.

Authors:  Sunee Chansangpetch; Natnaree Taechajongjintana; Kitiya Ratanawongphaibul; Rath Itthipanichpong; Anita Manassakorn; Visanee Tantisevi; Prin Rojanapongpun; Shan C Lin
Journal:  Sci Rep       Date:  2022-09-30       Impact factor: 4.996

8.  Topical Anesthesia Offers Sufficient Pain Control for MicroPulse Transscleral Laser Therapy for Glaucoma.

Authors:  Belgin Vasella; Marc Töteberg-Harms
Journal:  J Ophthalmol       Date:  2022-09-21       Impact factor: 1.974

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.